Testing TCP-25 Gel for Epidermolysis Bullosa
Part of Genetic & congenital, Skin clinical trials.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of either DEB or JEB (dystrophic or junctional epidermolysis bullosa).
- You must be at least 4 years old (and at least 12 years old for initial enrollment).
- You cannot have any other type of epidermolysis bullosa besides DEB or JEB.
- You cannot be taking antibiotics by mouth or through a vein right now (some exceptions apply).
- You cannot have used steroid creams or ointments on the study wounds in the week before the screening visit.
- You must not have a current or past skin cancer (like basal or squamous cell) in the area being treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called oleogel-S10 on wounds caused by a rare skin condition called epidermolysis bullosa (EB). It is only for people of Japanese descent who have a specific type of EB called junctional or dystrophic EB. The gel is put on the wound to help it heal.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
This study evaluates pz-cel, a personalized skin cell treatment for wounds caused by dystrophic epidermolysis bullosa (a genetic condition causing fragile skin). It provides access to the treatment when the manufactured product doesn't meet standard release, or for patients needing special access, and helps ensure its safety and effectiveness.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.